<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Schiebler M</submitter><funding>Medical Research Council</funding><funding>Wellcome Trust</funding><funding>Biotechnology and Biological Sciences Research Council</funding><pagination>127-39</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4328644</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>7(2)</volume><pubmed_abstract>Mycobacterium tuberculosis (MTB) remains a major challenge to global health made worse by the spread of multidrug resistance. We therefore examined whether stimulating intracellular killing of mycobacteria through pharmacological enhancement of macroautophagy might provide a novel therapeutic strategy. Despite the resistance of MTB to killing by basal autophagy, cell-based screening of FDA-approved drugs revealed two anticonvulsants, carbamazepine and valproic acid, that were able to stimulate autophagic killing of intracellular M. tuberculosis within primary human macrophages at concentrations achievable in humans. Using a zebrafish model, we show that carbamazepine can stimulate autophagy in vivo and enhance clearance of M. marinum, while in mice infected with a highly virulent multidrug</pubmed_abstract><journal>EMBO molecular medicine</journal><pubmed_title>Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion.</pubmed_title><pmcid>PMC4328644</pmcid><funding_grant_id>100140</funding_grant_id><funding_grant_id>MC_U105115237</funding_grant_id><funding_grant_id>MR/M004864/1</funding_grant_id><funding_grant_id>095317</funding_grant_id><funding_grant_id>G108/595</funding_grant_id><funding_grant_id>G0701932</funding_grant_id><funding_grant_id>BBS/E/B/000C0415</funding_grant_id><pubmed_authors>Renna M</pubmed_authors><pubmed_authors>Basaraba R</pubmed_authors><pubmed_authors>Rubinsztein DC</pubmed_authors><pubmed_authors>Henao Tamayo M</pubmed_authors><pubmed_authors>Anderson KE</pubmed_authors><pubmed_authors>Obregon-Henao A</pubmed_authors><pubmed_authors>Ordway DJ</pubmed_authors><pubmed_authors>Hawkins PT</pubmed_authors><pubmed_authors>Newton SM</pubmed_authors><pubmed_authors>Renshaw SA</pubmed_authors><pubmed_authors>Coulter S</pubmed_authors><pubmed_authors>Fleming A</pubmed_authors><pubmed_authors>Kay RR</pubmed_authors><pubmed_authors>Brown K</pubmed_authors><pubmed_authors>Henry KM</pubmed_authors><pubmed_authors>Kampmann B</pubmed_authors><pubmed_authors>Floto RA</pubmed_authors><pubmed_authors>Hegyi K</pubmed_authors><pubmed_authors>Klapholz C</pubmed_authors><pubmed_authors>Hepburn L</pubmed_authors><pubmed_authors>Schiebler M</pubmed_authors><pubmed_authors>Burgon J</pubmed_authors></additional><is_claimable>false</is_claimable><name>Functional drug screening reveals anticonvulsants as enhancers of mTOR-independent autophagic killing of Mycobacterium tuberculosis through inositol depletion.</name><description>Mycobacterium tuberculosis (MTB) remains a major challenge to global health made worse by the spread of multidrug resistance. We therefore examined whether stimulating intracellular killing of mycobacteria through pharmacological enhancement of macroautophagy might provide a novel therapeutic strategy. Despite the resistance of MTB to killing by basal autophagy, cell-based screening of FDA-approved drugs revealed two anticonvulsants, carbamazepine and valproic acid, that were able to stimulate autophagic killing of intracellular M. tuberculosis within primary human macrophages at concentrations achievable in humans. Using a zebrafish model, we show that carbamazepine can stimulate autophagy in vivo and enhance clearance of M. marinum, while in mice infected with a highly virulent multidrug</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015 Feb</publication><modification>2025-04-04T10:01:39.149Z</modification><creation>2019-03-27T01:45:13Z</creation></dates><accession>S-EPMC4328644</accession><cross_references><pubmed>25535254</pubmed><doi>10.15252/emmm.201404137</doi></cross_references></HashMap>